{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T01:46:02Z","timestamp":1789436762597,"version":"build-2803163510"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","msard-journal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.msard.2024.105605","type":"journal-article","created":{"date-parts":[[2024,4,19]],"date-time":"2024-04-19T02:54:09Z","timestamp":1713495249000},"page":"105605","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Switching from natalizumab to an anti-CD20 monoclonal antibody in relapsing remitting multiple sclerosis: A systematic review"],"prefix":"10.1016","volume":"86","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-9968-4061","authenticated-orcid":false,"given":"Justin D.","family":"Brown","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin T.","family":"Muston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Massey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.msard.2024.105605_bib0001","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1002\/ana.24651","article-title":"Rituximab versus fingolimod after natalizumab in multiple sclerosis patients","volume":"79","author":"Alping","year":"2016","journal-title":"Ann. Neurol."},{"issue":"19","key":"10.1016\/j.msard.2024.105605_bib0002","doi-asserted-by":"crossref","first-page":"e1778","DOI":"10.1212\/WNL.0000000000008189","article-title":"Onset of clinical and MRI efficacy of ocrelizumab in relapsing multiple sclerosis","volume":"93","author":"Barkhof","year":"2019","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2024.105605_bib0003","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.103076","article-title":"How to switch disease-modifying treatments in multiple sclerosis: Guidelines from the French Multiple Sclerosis Society (SFSEP)","volume":"53","author":"Bigaut","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2024.105605_bib0004","doi-asserted-by":"crossref","DOI":"10.1007\/s00415-021-10950-7","article-title":"Ocrelizumab versus fingolimod after natalizumab cessation in multiple sclerosis: an observational study","author":"Bigaut","year":"2022","journal-title":"J. Neurol."},{"issue":"20","key":"10.1016\/j.msard.2024.105605_bib0005","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1056\/NEJMoa1107829","article-title":"Risk of natalizumab-associated progressive multifocal leukoencephalopathy","volume":"366","author":"Bloomgren","year":"2012","journal-title":"N. Engl. J. Med."},{"issue":"20","key":"10.1016\/j.msard.2024.105605_bib0006","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1212\/WNL.0000000000003345","article-title":"Rituximab for treating multiple sclerosis","volume":"87","author":"Bourdette","year":"2016","journal-title":"Neurology"},{"issue":"7","key":"10.1016\/j.msard.2024.105605_bib0007","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1016\/S1474-4422(22)00143-0","article-title":"Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA): a randomised, controlled, open-label, phase 3b trial","volume":"21","author":"Foley","year":"2022","journal-title":"Lancet Neurol."},{"issue":"3","key":"10.1016\/j.msard.2024.105605_bib0008","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1007\/s13311-021-01102-w","article-title":"Multiple sclerosis: switching from natalizumab to other high-efficacy treatments to mitigate progressive multifocal leukoencephalopathy risk","volume":"18","author":"Hartung","year":"2021","journal-title":"Neurotherapeutics"},{"issue":"10","key":"10.1016\/j.msard.2024.105605_bib0009","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1177\/13524585221079731","article-title":"Safety experience with continued exposure to ofatumumab in patients with relapsing forms of multiple sclerosis for up to 3.5 years","volume":"28","author":"Hauser","year":"2022","journal-title":"Mult. Scler."},{"issue":"7","key":"10.1016\/j.msard.2024.105605_bib0010","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1056\/NEJMoa0706383","article-title":"B-cell depletion with rituximab in relapsing-remitting multiple sclerosis","volume":"358","author":"Hauser","year":"2008","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"10.1016\/j.msard.2024.105605_bib0011","first-page":"109","article-title":"Progressive multifocal leukoencephalopathy: current insights","volume":"2","author":"Kartau","year":"2019","journal-title":"Degener. Neurol. Neuromuscul. Dis."},{"issue":"5","key":"10.1016\/j.msard.2024.105605_bib0012","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1007\/s40265-023-01854-z","article-title":"Ublituximab: first approval","volume":"83","author":"Lee","year":"2023","journal-title":"Drugs"},{"issue":"5","key":"10.1016\/j.msard.2024.105605_bib0013","article-title":"Ocrelizumab for multiple sclerosis","volume":"5","author":"Lin","year":"2022","journal-title":"Cochrane Database Syst. Rev."},{"issue":"5","key":"10.1016\/j.msard.2024.105605_bib0014","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1177\/1352458520946017","article-title":"Switching to ocrelizumab in RRMS patients at risk of PML previously treated with extended interval dosing of natalizumab","volume":"27","author":"Mancinelli","year":"2021","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2024.105605_bib0015","series-title":"Development of a Quality Appraisal Tool for Case Series Studies Using a Modified Delphi Technique","author":"Moga","year":"2012"},{"key":"10.1016\/j.msard.2024.105605_bib0016","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.103995","article-title":"Use of natalizumab in persons with multiple sclerosis: 2022 update","volume":"65","author":"Morrow","year":"2022","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2024.105605_bib0017","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"issue":"6","key":"10.1016\/j.msard.2024.105605_bib0018","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1177\/1756285615602832","article-title":"Progressive multifocal leukoencephalopathy: current treatment options and future perspectives","volume":"8","author":"Pavlovic","year":"2015","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"10.1016\/j.msard.2024.105605_bib0019","article-title":"Natalizumab extended-interval dosing in multiple sclerosis to mitigate progressive multifocal leukoencephalopathy risk: initial study evidence and real-world experience","volume":"14","author":"Perncezky","year":"2022","journal-title":"J. Cent. Nerv. Syst. Dis."},{"issue":"9","key":"10.1016\/j.msard.2024.105605_bib0020","doi-asserted-by":"crossref","DOI":"10.3390\/v13091684","article-title":"Risk assessment of progressive multifocal leukoencephalopathy in multiple sclerosis patients during 1 year of ocrelizumab treatment","volume":"13","author":"Prezioso","year":"2021","journal-title":"Viruses"},{"key":"10.1016\/j.msard.2024.105605_bib0021","doi-asserted-by":"crossref","DOI":"10.1177\/1756286419837809","article-title":"Post-natalizumab disease reactivation in multiple sclerosis: systematic review and meta-analysis","volume":"12","author":"Prosperini","year":"2019","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"10.1016\/j.msard.2024.105605_bib0022","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1086028","article-title":"Switch to ocrelizumab in MS patients treated with natalizumab in extended interval dosing at high risk of PML: A 96-week follow-up pilot study","volume":"14","author":"Santiago-Setien","year":"2023","journal-title":"Front. Immunol."},{"issue":"9","key":"10.1016\/j.msard.2024.105605_bib0023","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.3174\/ajnr.A2226","article-title":"Natalizumab (Tysabri)","volume":"31","author":"Selewski","year":"2010","journal-title":"Am. J. Neuroradiol."},{"issue":"2","key":"10.1016\/j.msard.2024.105605_bib0024","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","article-title":"Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria","volume":"17","author":"Thompson","year":"2017","journal-title":"Lancet Neurol."},{"issue":"2","key":"10.1016\/j.msard.2024.105605_bib0025","article-title":"Ocrelizumab after natalizumab in JC-virus positive relapsing remitting multiple sclerosis patients","volume":"7","author":"van Lierop","year":"2021","journal-title":"Mult. Scler. J. Exp. Transl. Clin."},{"issue":"13 Pt 2","key":"10.1016\/j.msard.2024.105605_bib0026","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1212\/01.wnl.0000265393.03231.e5","article-title":"Postwithdrawal rebound increase in T2 lesional activity in natalizumab-treated MS patients","volume":"70","author":"Vellinga","year":"2008","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2024.105605_bib0027","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1186\/1471-2288-14-135","article-title":"Estimating the sample mean and standard deviation from the sample size, median, range and\/or interquartile range","volume":"14","author":"Wan","year":"2014","journal-title":"BMC Med. Res. Methodol."},{"issue":"2","key":"10.1016\/j.msard.2024.105605_bib0028","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1007\/s13311-021-01037-2","article-title":"Exit strategies in natalizumab-treated RRMS at high risk of progressive multifocal leukoencephalopathy: a multicentre comparison study","volume":"18","author":"Zanghi","year":"2021","journal-title":"Neurotherapeutics"}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034824001846?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034824001846?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,6]],"date-time":"2024-05-06T23:21:40Z","timestamp":1715037700000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034824001846"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":28,"alternative-id":["S2211034824001846"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2024.105605","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Switching from natalizumab to an anti-CD20 monoclonal antibody in relapsing remitting multiple sclerosis: A systematic review","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2024.105605","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"105605"}}